{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:58Z","timestamp":1790767318795,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clp.2023.11.008","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T07:18:06Z","timestamp":1702106286000},"page":"113-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeted Therapies for Neonatal Pulmonary Hypertension: Beyond Nitric Oxide"],"prefix":"10.1016","volume":"51","author":[{"given":"Jeanne","family":"Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin H.","family":"Steinhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12887-019-1400-3","article-title":"Developmental outcomes of preterm infants with bronchopulmonary dysplasia-associated pulmonary hypertension at 18-24\u00a0months of corrected age","volume":"19","author":"Choi","year":"2019","journal-title":"BMC Pediatr"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019878598","article-title":"Diminished right ventricular function at diagnosis of pulmonary hypertension is associated with mortality in bronchopulmonary dysplasia","volume":"9","author":"Altit","year":"2019","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib3","doi-asserted-by":"crossref","first-page":"e20161165","DOI":"10.1542\/peds.2016-1165","article-title":"Persistent pulmonary hypertension of the newborn in late preterm and term infants in California","volume":"139","author":"Steurer","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jpeds.2006.11.065","article-title":"Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up","volume":"150","author":"Konduri","year":"2007","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1542\/peds.2007-0971","article-title":"Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era","volume":"120","author":"Khemani","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0095-5108(18)30039-3","article-title":"Pulmonary vascular biology during neonatal transition","volume":"26","author":"Lakshminrusimha","year":"1999","journal-title":"Clin Perinatol"},{"issue":"5","key":"10.1016\/j.clp.2023.11.008_bib7","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.clp.2023.11.008_bib8","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clp.2023.11.008_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A\u00a0randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.clp.2023.11.008_bib10","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.113.005698","article-title":"STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension","volume":"129","author":"Barst","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0029-1239496","article-title":"The use of sildenafil in persistent pulmonary hypertension of the newborn","volume":"27","author":"Vargas-Origel","year":"2010","journal-title":"Am J Perinatol"},{"issue":"7","key":"10.1016\/j.clp.2023.11.008_bib12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1164\/rccm.201606-1183ST","article-title":"Executive summary of the American heart association and American thoracic society joint guidelines for pediatric pulmonary hypertension","volume":"194","author":"Abman","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jpeds.2009.06.012","article-title":"Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension","volume":"155","author":"Steinhorn","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.clp.2023.11.008_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jpeds.2021.05.051","article-title":"Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of, persistent pulmonary hypertension of the newborn (PPHN): a multicenter, randomized, placebo-controlled trial","volume":"237","author":"Pierce","year":"2021","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ppul.23508","article-title":"Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia","volume":"52","author":"Kadmon","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jpeds.2008.09.021","article-title":"Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease","volume":"154","author":"Mourani","year":"2009","journal-title":"J\u00a0Pediatr"},{"issue":"8","key":"10.1016\/j.clp.2023.11.008_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00431-015-2515-7","article-title":"Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety","volume":"174","author":"Tan","year":"2015","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/jp.2011.131","article-title":"Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?","volume":"32","author":"Nyp","year":"2012","journal-title":"J\u00a0Perinatol"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00246-015-1154-0","article-title":"Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmonary dysplasia","volume":"36","author":"Trottier-Boucher","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.clp.2023.11.008_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpeds.2018.09.067","article-title":"Sildenafil use in children with pulmonary hypertension","volume":"205","author":"Cohen","year":"2019","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-0038-1667378","article-title":"Sildenafil exposure in the neonatal intensive care unit","volume":"36","author":"Thompson","year":"2019","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.clp.2023.11.008_bib22","doi-asserted-by":"crossref","first-page":"101025","DOI":"10.1016\/j.conctc.2022.101025","article-title":"Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: rationale and methods of a phase II randomized trial","volume":"30","author":"Lang","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"11","key":"10.1016\/j.clp.2023.11.008_bib23","doi-asserted-by":"crossref","first-page":"e032122","DOI":"10.1136\/bmjopen-2019-032122","article-title":"The CoDiNOS trial protocol: an international randomised controlled trial of intravenous sildenafil versus inhaled nitric oxide for the treatment of pulmonary hypertension in neonates with congenital diaphragmatic hernia","volume":"9","author":"Cochius-den Otter","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.clp.2023.11.008_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.niox.2018.05.009","article-title":"Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential","volume":"78","author":"Buys","year":"2018","journal-title":"Nitric Oxide"},{"issue":"5","key":"10.1016\/j.clp.2023.11.008_bib25","doi-asserted-by":"crossref","first-page":"L755","DOI":"10.1152\/ajplung.00138.2010","article-title":"Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension","volume":"301","author":"Chester","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib27","doi-asserted-by":"crossref","first-page":"e12133","DOI":"10.1002\/pul2.12133","article-title":"Riociguat in children with pulmonary arterial hypertension: the PATENT\u2013CHILD study","volume":"12","author":"Garc\u00eda Aguilar","year":"2022","journal-title":"Pulm Circ"},{"key":"10.1016\/j.clp.2023.11.008_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jpeds.2022.11.026","article-title":"Safety and feasibility of riociguat therapy for the treatment of chronic pulmonary arterial hypertension in infancy","volume":"255","author":"Giesinger","year":"2023","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-3476(05)81552-5","article-title":"Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension","volume":"123","author":"Rosenberg","year":"1993","journal-title":"J\u00a0Pediatr"},{"issue":"24","key":"10.1016\/j.clp.2023.11.008_bib30","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev.med.59.110106.212434","article-title":"Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension","volume":"60","author":"Abman","year":"2009","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.semperi.2015.12.004","article-title":"Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide","volume":"40","author":"Lakshminrusimha","year":"2016","journal-title":"Semin Perinatol"},{"issue":"38","key":"10.1016\/j.clp.2023.11.008_bib33","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","article-title":"Effects of long-term bosentan in children with pulmonary arterial hypertension","volume":"46","author":"Rosenzweig","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.clp.2023.11.008_bib35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/hrt.2005.072314","article-title":"Response to bosentan in children with pulmonary hypertension","volume":"92","author":"Maiya","year":"2006","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension","volume":"73","author":"Barst","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.clp.2023.11.008_bib37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/jp.2011.157","article-title":"A\u00a0randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn","volume":"32","author":"Mohamed","year":"2012","journal-title":"J\u00a0Perinatol"},{"key":"10.1016\/j.clp.2023.11.008_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpeds.2016.06.078","article-title":"Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial","volume":"177","author":"Steinhorn","year":"2016","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40272-023-00573-y","article-title":"Macitentan in the young\u2014mid-term outcomes of patients with pulmonary hypertensive vascular disease treated in a pediatric tertiary care center","volume":"25","author":"Albinni","year":"2023","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ppul.22555","article-title":"Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension","volume":"48","author":"Takatsuki","year":"2013","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/ppul.25796","article-title":"Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: real-world experience","volume":"57","author":"Issapour","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.clp.2023.11.008_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1203\/PDR.0b013e318179954c","article-title":"Safety experience with bosentan in 146 children 2\u201311 Years old with pulmonary arterial hypertension: results from the European postmarketing surveillance program","volume":"64","author":"Beghetti","year":"2008","journal-title":"Pediatr Res"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/17476348.2017.1317599","article-title":"The prostacyclin pathway in pulmonary arterial hypertension: a clinical review","volume":"11","author":"Del Pozo","year":"2017","journal-title":"Expet Rev Respir Med"},{"issue":"2","key":"10.1016\/j.clp.2023.11.008_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.clp.2023.11.008_bib45","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","article-title":"Vasodilator therapy for primary pulmonary hypertension in children","volume":"99","author":"Barst","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.1016\/j.clp.2023.11.008_bib47","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.clp.2023.11.008_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/children7080097","article-title":"Targeted therapy for pulmonary hypertension in premature infants","volume":"7","author":"Nees","year":"2020","journal-title":"Children"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ppul.20238","article-title":"Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease","volume":"40","author":"Zaidi","year":"2005","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.clp.2023.11.008_bib50","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41372-018-0179-7","article-title":"Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide","volume":"38","author":"Ahmad","year":"2018","journal-title":"J\u00a0Perinatol"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib51","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.98.12040932","article-title":"Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension","volume":"12","author":"De Jaegere","year":"1998","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib52","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1067\/mpd.2002.129849","article-title":"Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide","volume":"141","author":"Kelly","year":"2002","journal-title":"J\u00a0Pediatr"},{"issue":"11","key":"10.1016\/j.clp.2023.11.008_bib53","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1055\/s-0038-1676483","article-title":"Inhaled epoprostenol for pulmonary hypertension treatment in neonates: a 12-year experience","volume":"36","author":"Berger-Caron","year":"2019","journal-title":"Am J Perinatol"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1017\/S1047951103000726","article-title":"Iloprost in persistent pulmonary hypertension of the newborn","volume":"13","author":"Ehlen","year":"2003","journal-title":"Cardiol Young"},{"issue":"13","key":"10.1016\/j.clp.2023.11.008_bib55","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1055\/s-0040-1722653","article-title":"Effects of inhaled iloprost for the management of persistent pulmonary hypertension of the newborn","volume":"39","author":"Verma","year":"2022","journal-title":"Am J Perinatol"},{"issue":"12","key":"10.1016\/j.clp.2023.11.008_bib56","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ppul.22985","article-title":"Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn","volume":"49","author":"Kahveci","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"04","key":"10.1016\/j.clp.2023.11.008_bib57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-0033-1348949","article-title":"Inhaled iloprost in preterm infants with severe respiratory distress syndrome and pulmonary hypertension","volume":"31","author":"Yilmaz","year":"2013","journal-title":"Am J Perinatol"},{"issue":"8","key":"10.1016\/j.clp.2023.11.008_bib58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ppul.21619","article-title":"Nebulized iloprost and noninvasive respiratory support for impending hypoxaemic respiratory failure in formerly preterm infants: a case series","volume":"47","author":"Piastra","year":"2012","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.clp.2023.11.008_bib59","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4070\/kcj.2009.39.8.343","article-title":"Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension","volume":"39","author":"Hwang","year":"2009","journal-title":"Korean Circ J"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib60","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ppul.21415","article-title":"Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension","volume":"46","author":"G\u00fcrakan","year":"2011","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib61","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clp.2023.11.008_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijcard.2018.03.067","article-title":"Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension","volume":"264","author":"Levy","year":"2018","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.clp.2023.11.008_bib63","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.amjcard.2012.07.037","article-title":"Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children","volume":"110","author":"Krishnan","year":"2012","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib64","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jpeds.2015.06.016","article-title":"Short-term treprostinil use in infants with congenital diaphragmatic hernia following repairs","volume":"167","author":"Olson","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"9","key":"10.1016\/j.clp.2023.11.008_bib65","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jpedsurg.2017.03.058","article-title":"Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension","volume":"52","author":"Carpentier","year":"2017","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.clp.2023.11.008_bib66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpeds.2018.04.052","article-title":"Treprostinil improves persistent pulmonary hypertension associated with congenital diaphragmatic hernia","volume":"200","author":"Lawrence","year":"2018","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.clp.2023.11.008_bib67","doi-asserted-by":"crossref","first-page":"113420","DOI":"10.1016\/j.jpeds.2023.113420","article-title":"Treprostinil in neonates with congenital diaphragmatic hernia-related pulmonary hypertension","volume":"259","author":"De Bie","year":"2023","journal-title":"J\u00a0Pediatr"},{"issue":"26","key":"10.1016\/j.clp.2023.11.008_bib68","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2023.11.008_bib69","doi-asserted-by":"crossref","first-page":"1055158","DOI":"10.3389\/fped.2023.1055158","article-title":"A\u00a0Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients","volume":"11","author":"Youssef","year":"2023","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019876545","article-title":"Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension","volume":"10","author":"Rothman","year":"2020","journal-title":"Pulm Circ"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib71","doi-asserted-by":"crossref","first-page":"e12159","DOI":"10.1002\/pul2.12159","article-title":"Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension","volume":"12","author":"Colglazier","year":"2022","journal-title":"Pulm Circ"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib72","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1017\/S1047951119001082","article-title":"Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension","volume":"29","author":"Koo","year":"2019","journal-title":"Cardiol Young"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/PCC.0b013e31824ea2cd","article-title":"Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide\u2217","volume":"14","author":"McNamara","year":"2013","journal-title":"Pediatr Crit Care Med"},{"issue":"2","key":"10.1016\/j.clp.2023.11.008_bib74","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jcrc.2006.01.001","article-title":"Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn","volume":"21","author":"McNamara","year":"2006","journal-title":"J\u00a0Crit Care"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib75","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/S1047951114002698","article-title":"The effect of milrinone on right and left ventricular function when used as a rescue therapy for term infants with pulmonary hypertension","volume":"26","author":"James","year":"2016","journal-title":"Cardiol Young"},{"issue":"1","key":"10.1016\/j.clp.2023.11.008_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41372-021-01228-x","article-title":"Worsened short-term clinical outcomes in a cohort of patients with iNO-unresponsive PPHN: a case for improving iNO responsiveness","volume":"42","author":"Dillard","year":"2022","journal-title":"J\u00a0Perinatol"},{"issue":"2","key":"10.1016\/j.clp.2023.11.008_bib77","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41372-022-01562-8","article-title":"The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1)","volume":"43","author":"EL-Khuffash","year":"2023","journal-title":"J\u00a0Perinatol"},{"issue":"2","key":"10.1016\/j.clp.2023.11.008_bib78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000339108","article-title":"Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension secondary to congenital diaphragmatic hernia: a review of six patients","volume":"102","author":"Patel","year":"2012","journal-title":"Neonatology"},{"issue":"03","key":"10.1016\/j.clp.2023.11.008_bib79","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0039-1678558","article-title":"Is milrinone effective for infants with mild-to-moderate congenital diaphragmatic hernia?","volume":"37","author":"Mears","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.clp.2023.11.008_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40748-017-0066-9","article-title":"Milrinone in congenital diaphragmatic hernia \u2013 a randomized pilot trial: study protocol, review of literature and survey of current practices","volume":"3","author":"Lakshminrusimha","year":"2017","journal-title":"Matern Health Neonatol Perinatol"},{"issue":"3","key":"10.1016\/j.clp.2023.11.008_bib81","first-page":"231","article-title":"Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger Syndrome: a clinical trial","volume":"64","author":"Sharif Kashani","year":"2014","journal-title":"J\u00a0Cardiol"},{"issue":"2","key":"10.1016\/j.clp.2023.11.008_bib82","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1165\/rcmb.2014-0351OC","article-title":"Rescue treatment with L-citrulline inhibits hypoxia-induced pulmonary hypertension in newborn pigs","volume":"53","author":"Fike","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/ph16040503","article-title":"Pharmacotherapy for pulmonary hypertension in infants with bronchopulmonary dysplasia: past, present, and future","volume":"16","author":"Fike","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.clp.2023.11.008_bib84","doi-asserted-by":"crossref","first-page":"L979","DOI":"10.1152\/ajplung.90238.2008","article-title":"Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension","volume":"295","author":"Farrow","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"12","key":"10.1016\/j.clp.2023.11.008_bib85","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1164\/rccm.200605-676OC","article-title":"Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension","volume":"174","author":"Lakshminrusimha","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib86","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.jp.7200363","article-title":"Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase","volume":"20","author":"Davis","year":"2000","journal-title":"J\u00a0Perinatol"},{"issue":"4","key":"10.1016\/j.clp.2023.11.008_bib87","doi-asserted-by":"crossref","first-page":"L743","DOI":"10.1152\/ajplung.00238.2016","article-title":"Tetrahydrobiopterin oral therapy recouples eNOS and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs","volume":"311","author":"Dikalova","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"8","key":"10.1016\/j.clp.2023.11.008_bib88","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.placenta.2014.05.003","article-title":"Placental pathologic changes of maternal vascular underperfusion in bronchopulmonary dysplasia and pulmonary hypertension","volume":"35","author":"Mestan","year":"2014","journal-title":"Placenta"},{"issue":"7","key":"10.1016\/j.clp.2023.11.008_bib89","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/jp.2012.164","article-title":"Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia","volume":"33","author":"Check","year":"2013","journal-title":"J\u00a0Perinatol Off J Calif Perinat Assoc"},{"issue":"9","key":"10.1016\/j.clp.2023.11.008_bib90","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1164\/rccm.201910-1975OC","article-title":"rhIGF-1\/BP3 preserves lung growth and prevents pulmonary hypertension in experimental bronchopulmonary dysplasia","volume":"201","author":"Seedorf","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510823001136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510823001136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:01:03Z","timestamp":1758816063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510823001136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0095510823001136"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2023.11.008","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapies for Neonatal Pulmonary Hypertension: Beyond Nitric Oxide","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}